MLICM
SMMT icon

Metropolitan Life Insurance Company (MetLife)’s Summit Therapeutics SMMT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,561
Closed -$27.2K – 1800
2024
Q1 		$27.2K Hold
6,561
– – ﹤0.01% 1709
2023
Q4 		$17.1K Hold
6,561
– – ﹤0.01% 1983
2023
Q3 		$12.3K Hold
6,561
– – ﹤0.01% 2126
2023
Q2 		$16.5K Buy
+6,561
New +$12K ﹤0.01% 2032

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SMMT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Summit Therapeutics (SMMT) in Q2 2024, closing a stake of 6,561 shares — an estimated $27.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SMMT in Q2 2023 and held it in 4 quarters. The position peaked at $27.2K in Q1 2024. 123 funds tracked by Wall St. Rank hold SMMT as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Summit Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 6,561 Summit Therapeutics shares in Q2 2024, an estimated $27.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Summit Therapeutics in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Summit Therapeutics position peaked at $27.2K in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.